CompletedPhase 2NCT02967653

Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus

Studying Arginine vasopressin resistance

Last synced from ClinicalTrials.gov May 4, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Lady Davis Institute
Principal Investigator: Soham F Rej, MD, M.Sc.
Jewish General Hospital
Intervention: Atorvastatin(drug)
Enrollment: 60 enrolled
Eligibility: 18-85 years · All sexes
Timeline: 2017 – 2019

Study locations (3)

McGill University Health Centre, Montreal, Quebec, Canada
Jewish General Hospital, Montreal, Quebec, Canada
Douglas Mental Health University Institute, Montreal, Quebec, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02967653 on ClinicalTrials.gov

Other trials for Arginine vasopressin resistance

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE4NCT05044611
AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium
Assistance Publique - Hôpitaux de Paris

See all trials for Arginine vasopressin resistance →

← Back to all trials